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Abstract
Objective. Endometriosis is a frequent indication for in vitro fertilization and em-
bryo transfer (IVF-ET). Its influence on IVF-ET cycles remains controversial. We
evaluated the impact of the severity of endometriosis on IVF-ET cycles in young
women. Design. Retrospective cohort study. Setting. Academic tertiary referral cen-
tre. Sample and Methods. In a retrospective cohort analysis, 164 IVF-ET cycles in
148 women with endometriosis-associated infertility were analyzed. Eighty cycles
performed during the same period on 72 consecutive women with tubal infertility
were considered as controls. All patients were younger than 35 years old. Main Out-
come Measures. Response to controlled ovarian hyperstimulation (COH), number
of oocytes retrieved, fertilization, implantation and pregnancy rate (PR). Results.
Clinical PR was lower in the group with endometriosis (all stages) in compari-
son with the tubal factor group. Higher total gonadotropin requirements, lower
response to COH and lower oocyte yield were also found in the endometriosis
group. Stage-stratified analysis showed a lower fertilization rate in stage I–II (52.6%
stage I–II, 70.5% stage III–IV and 71.9% tubal factor). In stage III–IV endometriosis
there was a higher cycle cancellation rate, a reduced response to COH and a lower
PR compared with both the stage I–II and the tubal infertility groups (PR 9.7, 25
and 26.1%, respectively). Conclusions. Stage III–IV was strongly associated with
poor IVF outcome. A decreased fertilization rate in stage I–II might be a cause of
subfertility in these women, owing to a hostile environment caused by the disease.
Abbreviations: ASRM, American Society for Reproductive Medicine; COH, con-
trolled ovarian hyperstimulation; E2, estradiol; FSH, follicle-stimulating hormone;
hCG, human chorionic gonadotropin; IVF, in vitro fertilization; IVF-ET, in vitro
fertilization and embryo transfer; PR, pregnancy rate
Introduction
Endometriosis is a well-known cause of subfertility. The re-
ported prevalence of endometriosis found at laparoscopy in
infertile women is 25–35%, whereas the prevalence in the
general population is 3–12% (1,2). This high prevalence of
endometriosis in infertile women has led to the assumption
that there might be a causal relation between endometriosis
and infertility.
According to European Society of Human Reproduction
and Embryology guidelines, in vitro fertilization and embryo
transfer (IVF-ET) is an appropriate treatment in cases of in-
fertility with a history of endometriosis, especially when asso-
ciated with compromised tubal function, male factor and/or
other treatment failures (3). In a meta-analysis of 22 studies
from 1983 to 1997, Barnhart et al. (4) concluded that, overall,
endometriosis significantly reduces all markers of the repro-
ductive process, which results in an IVF pregnancy rate that is
1232
C© 2011 The Authors
Acta Obstetricia et Gynecologica Scandinavica C© 2011 Nordic Federation of Societies of Obstetrics and Gynecology 90 (2011) 1232–1238
A C TA  Obstetricia et Gynecologica
M.E. Coccia et al. Endometriosis and in vitro fertilization
almost one-half that for women who undergo IVF for other
indications. However, several limitations must be considered
when interpreting these results: the meta-analysis did not
include randomized controlled trials; some of the included
studies were outdated and did not take into account improve-
ments of the IVF-ET protocols and laboratory performances
in the last decade; the outcome reported for each study var-
ied, with some studies reporting absolute pregnancy rates,
some reporting clinical pregnancy rates and some live birth
rates; and articles could not be categorized as to whether the
endometriosis was medically or surgically treated before the
initiation of IVF-ET or whether endometriotic lesions were
present at the time of the cycle (4).
Analysis of large databases (such as Society for Assisted
Reproductive Technology (SART) and Human Fertilisation
and Embryology Authority (HFEA)) indicates that there is
no difference in IVF-ET outcome for women with infertility-
related endometriosis. In a more recent publication, Matal-
liotakis et al. compared the IVF-ET outcomes of 68 women
who previously underwent laparoscopic surgery for advanced
stage endometriosis and a control group of 106 women with
tubal factor infertility. They reported that women with ad-
vanced stage endometriosis and previous surgery responded
less well to gonadotropin stimulation, but had similar IVF-
ET implantation and delivery rates compared with women
with tubal factor infertility (5). Thus, the question of whether
endometriosis affects the outcome of IVF-ET cycles has not
been resolved. Furthermore, the effect of different stages of
endometriosis on IVF-ET outcome remains unclear.
The objective of this study was to evaluate the real effect
of endometriosis on the IVF-ET cycle parameters and out-
come in a carefully selected homogeneous group of young
patients who had been previously subjected to surgical treat-
ment for endometriosis, infertile before surgery for en-
dometriosis without clinical/ultrasonographic sign of recur-
rences. They were compared with a group of patients with
tubal infertility undergoing IVF-ET during the same period.
The effects of the different stages of endometriosis were also
analysed.
Material and methods
During the period from February 2001 to March 2007, 203
patients with the diagnosis of pelvic endometriosis under-
went IVF-ET in the Department of Science for the Woman
and Child’s Health (study group). Our study group consisted
of 148 patients with previous surgery for endometriosis. All
were infertile before surgery and did not show any clini-
cal/ultrasonographic signs of recurrence. Endometriosis was
stratified according to the severity of disease based on the
American Society for Reproductive Medicine (ASRM) re-
vised classification system for endometriosis into stage I–II
(minimal/mild) and stage III–IV (moderate/severe). The
control group included 72 women selected from patients with
tubal infertility who were undergoing IVF-ET in the same pe-
riod. They did not show any clinical/ultrasonographic signs
which raised suspicions of endometriosis.
In both groups, patients aged >35 years, with incomplete
clinical data and/or with other causes of infertility (such as
abnormal partner’s semen analysis according to the World
Health Organization criteria, infectious disease or a seriously
deformed uterus) were excluded.
Women with endometriosis-related infertility underwent
164 IVF-ET cycles, and patients of the control group 80 IVF-
ET cycles. To avoid a bias in the evaluation of the fertilization
rate, only IVF-ET cycles without intracytoplasmic sperm in-
jection were considered for analysis.
A ‘long-acting down-regulation’ drug regime was used.
Triptorelin (Decapeptyl R© 0.1mg, Ipsen Pharma, Milan, Italy)
was injected subcutaneously on day 21 of the cycle. After
down-regulation (verified after adequate ovarian suppres-
sion at pelvic ultrasonography and circulating estradiol (E2)
values below 35pg/ml), we initiated a daily subcutaneous ad-
ministration of 225–300IU of FSH (highly purified follicle-
stimulating hormone, Metrodin HP R©, 75IU, or recombi-
nant FSH, Gonal-F R©, 600IU; Serono, Rome, Italy). Doses
of gonadotropins were individually decided depending on
the patient’s age, basal FSH, ovarian volume, ovarian antral
follicle count and weight, and adjusted according to ovarian
response. Serial ultrasound scans and estradiol evaluations
were obtained during ovarian stimulations. When at least two
follicles reached a maximal diameter of 17–18mm, 10 000IU
of human chorionic gonadotropin (hCG; Gonasi R©, 5000IU,
two ampoules; Amsa, Rome, Italy) were subcutaneously ad-
ministered. Oocyte retrieval was 36hours later, using vaginal
ultrasonography, and the oocytes were fertilized on the same
day.
All oocytes retrieved were scored and inseminated for IVF-
ET (only three oocytes after the Assisted Reproduction Law
40/2004), and fertilization was assessed the following day.
Two or three days after the oocyte retrieval, the embryo trans-
fer was performed.
The luteal phase was supported with both a daily intra-
muscular administration of 50mg of natural progesterone
in oil (Prontogest R©; Amsa) and 600mg/day (Progeffik R©,
200mg; Effik, Cinisello Balsamo, Milan, Italy) beginning
on the night after ovum collection. Pregnancy was assessed
through plasma β-hCG values 14days after oocyte retrieval.
For patients with β-hCG >5IU/l of plasma, a transvaginal ul-
trasound scan was performed two weeks later. Clinical preg-
nancy was defined as the presence of at least one gestational
sac by ultrasound examination with a fetal pole and heart
activity.
Our primary end-points were the number of stimulation
days, number of FSH ampules, number of oocytes retrieved,
number of embryos transferred and clinical pregnancy rate.
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Table 1. Characteristics of patients.
Duration of infertility
Number of patients Number of cycles Age (years; mean±SD) Primary infertility (years; mean±SD)
n (Percentage)
Endometriosis
All stages 148 164 31.3±2.9 131 (88.5) 3.9±2.6
Stage I–II 54 55 31.8±3.3 45 (83.3) 4.8±2.7
Stage III–IV 94 109 31±2.5 86 (91.5) 3.3±2.4
Tubal factor 72 80 30.7±3.1 27 (37.5) 3.5±2.8
Note: Primary infertility in endometriosis (all stages, I–II and III–IV) vs. tubal factor: p=0.0001.
Secondary end-points included fertilization, implantation
and cancellation rates. The study design was approved by
our internal committee.
Statistical methods
Data are expressed as means±SD or percentages as required.
Statistical analyses were performed using a unpaired t-test
for parametric data or a χ2 test for categorical data. A
p-value <0.05 was considered to be significant. All statis-
tical analyses were performed using the Statistical Package
for Social Sciences software, version 18 (SPSS Inc., Chicago,
IL, USA).
Results
Patients in the two groups were comparable in terms of age
and duration of infertility. Most infertile women with en-
dometriosis had primary infertility (88.5% of women with
endometriosis vs. 37.5% of the tubal factor group) and were
treated earlier than women with tubal factor infertility (mean
infertility duration 3.9±2.6 years in endometriosis group and
3.5±2.8 years in control group; Table 1).
The semen characteristics of the study and control groups’
male partners are compared in Table 2. The mean (±SD)
sperm concentration proved similar. The mean percentage
of sperm with progressive motility was also comparable in
the study and control groups. The mean percentage of sperm
with normal morphological features was 42.4±24.3% in the
endometriosis group and 43.3±20.8% in the tubal factor
group.
Our initial analysis was to compare the endometriosis
group with women with tubal factor. Table 3 shows the over-
all outcomes of the IVF-ET cycles separately for women with
endometriosis and the control group. In spite of a higher FSH
dosage, the numbers of follicles on the day of hCG, oocytes
retrieved and embryos obtained and transferred were signif-
icantly fewer in women with endometriosis compared with
those without. No significant differences were found between
the groups with regard to the length of the stimulation phase,
cycle cancellation rate, peak E2 levels, fertilization or implan-
tation.
The statistical analysis demonstrated a significant decrease
in the chance of achieving a pregnancy for women with
endometriosis compared with women undergoing IVF for
tubal factor infertility. Nineteen (11.6%) clinical pregnancies
per started cycle were observed in women with endometrio-
sis, and 18 (22.5%) in women with tubal factor infertility
(p=0.041). The difference was not significant when clinical
pregnancy rates per retrieval or per embryo transfer were
considered.
To further investigate differential effects of IVF-ET out-
come by stage of endometriosis, we separately compared
Table 2. Comparison of semen characteristics between the endometriosis group and the control group.
Semen Partners of women Partners of women
characteristics with endometriosis with tubal factor p-Value
Ejaculate volume (ml) 3.7 ± 2.2 3.6 ± 1.7 NS
pH 7.7 ± 0.4 7.5 ± 0.3 NS
Sperm count (106/ml) 97.4 ± 71.3 92.1 ± 66.5 NS
Total sperm count (106 per ejaculate) 143.7 ± 47.7 212 ± 67.3 NS
Motility a (%)∗ 43.5 ± 27.7 37.8 ± 13.3 NS
Motility b (%)∗ 12.7 ± 7.5 18.1 ± 3.4 NS
Morphologically normal spermatozoa (%) 42.4 ± 24.3 43.3 ± 20.8 NS
∗Sperm motility is graded according to World Health Organization guidelines (WHO, 1999) (6): rapidly progressive (>25 μm s−1) (grade ‘a’), slowly
progressive (5–25 μm s−1) (grade ‘b’).
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Table 3. Results of analysis comparing endometriosis patients (any stage) with control women.
Endometriosis Tubal factor p-Value
Mean days on gonadotropins 11.8±1.9 11.7±1.9 0.779
Total FSH/hMG (IU) 3 842.1±1 692.2 3 301.9±1 421.7 0.016∗
Cycle cancellation rate 17 of 164 (10.4%) 3 of 80 (3.7%) 0.129
Peak E2 levels (pg/ml) 1 296.5±948.1 1 470.6±975.3 0.222
Number of follicles on day of hCG 11.6±6.5 14.6±6.5 0.001∗
Number of follicles ≥15mm on day of hCG 3.7±2.7 2.8±2.6 0.011∗
Number of of oocytes retrieved 7.8±5.4 10.8±6.1 0.001∗
Fertilization rate (%) 65.3 71.9 0.101
Total number of embryos 2.7±3.1 5±4 0.001∗
Mean number of transferred embryos 2.3±1.6 3.1±1.6 0.001∗
Total number of pregnancies (β-hCG+) 24 22 0.015∗
Number of clinical pregnancies 19 18 0.048∗
Implantation rate (%) 8.6 10.8 0.477
Clinical pregnancy rate per patient (19 of 148) 12.8% (18 of 72) 25% 0.038∗
Clinical pregnancy rate per started cycle (19 of 164) 11.6% (18 of 80) 22.5% 0.041∗
Clinical pregnancy rate per retrieval (19 of 147) 12.9% (18 of 77) 23.4% 0.070
Clinical pregnancy rate per embryo transfer (19 of 126) 15.1% (18 of 69) 26.1% 0.092
Abbreviations: hMG, human menopausal gonadotropins; FSH, follicle-stimulating hormone; β-hCG, β-subunit of human chorionic gonadotropin,
β-hCG+ when >5IU/l.
∗P < 0.05.
Table 4. Results of analysis comparing endometriosis patients (stage I–II and III–IV) with control women.
p-Value for p-Value for p-Value for
endometriosis endometriosis endometriosis
Endometriosis Endometriosis Tubal vs. stage I–II vs. stage III–IV vs. stage I–II
stage I–II stage III–IV factor tubal factor tubal factor stage III–IV
Mean days on gonadotropins 11.9±1.4 11.8±2.1 11.7±1.9 0.300 0.872 0.807
Total FSH/hMG (IU) 3 505.8±1 527.6 4 021.5±1 754.4 3 301.9±1 421.7 0.429 0.003∗ 0.065
Cycle cancellation rate 2 of 55 (3.6%) 15 of 109 (13.8%) 3 of 80 (3.7%) 0.668 0.039∗ 0.055
Peak E2 levels (pg/ml) 1 603.3±954.3 1 108.5±899.6 1 470.6±975.3 0.463 0.019∗ 0.004∗
Number of follicles on day of hCG 14.3±5.6 6.5±0.6 14.6±6.5 0.761 0.001∗ 0.001∗
Number of follicles ≥15mm on day of hCG 3.6±3.1 2.4±2.1 3.7±2.7 0.931 0.0001∗ 0.003∗
Number of oocytes retrieved 9.8±5.5 6.7±5 10.8±6.1 0.347 0.001∗ 0.001
Fertilization rate (%) 52.6 70.5 71.9 0.0001∗ 0.805 0.003∗
Total number of embryos 2.8±2.9 2.6±3.2 5±4 0.001∗ 0.001∗ 0.731
Mean number of transferred embryos 2.4±1.6 2.2±1.6 3.1±1.6 0.016∗ 0.001∗ 0.419
Total number of pregnancies (β-hCG+) 14 of 54 10 of 94 22 of 72 0.711 0.002∗ 0.028∗
Implantation rate (%) 14.1 5.3 10.8 0.453 0.055 0.010∗
Clinical pregnancy rate per patient (11 of 54) 20.4% (8 of 94) 8.5% (18 of 72) 25% 0.691 0.007∗ 0.069
Clinical pregnancy rate per started cycle (11 of 55) 20% (8 of 109) 7.3% (18 of 80) 22.5% 0.893 0.006∗ 0.033∗
Clinical pregnancy rate per retrieval (11 of 53) 20.7% (8 of 94) 8.5% (18 of 77) 23.4% 0.890 0.013∗ 0.062
Clinical pregnancy rate per embryo transfer (11 of 44) 25% (8 of 82) 9.7% (18 of 69) 26.1 % 0.927 0.015∗ 0.044∗
Abbreviations: hMG, human menopausal gonadotropins; FSH, follicle-stimulating hormone; β-hCG, β-subunit of human chorionic gonadotropin,
β-hCG+ when >5IU/l.
∗P < 0.05.
women with stage I–II endometriosis and those with
stage III–IV disease with women with tubal factor infertil-
ity. The results of both of these comparisons are presented in
Table 4. Patients with a confirmed diagnosis of endometriosis
stage I–II showed a significantly lower fertilization rate when
compared with the control group (52.6 vs. 71.9%, p=0.0001;
total number of embryos 2.8±2.9 vs. 5±4, p=0.001; and
mean number of transferred embryos 2.4±1.6 vs. 3.1±1.6,
p=0.001, respectively). Similar results were observed regard-
ing all the other outcomes.
A comparison of women with severe endometrio-
sis (stage III–IV) with women with tubal infertility
C© 2011 The Authors
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demonstrated a large reduction in the pregnancy rate. Signif-
icant differences were also observed in all the other compar-
isons; only the fertilization rate in stage III–IV endometriosis
was comparable to the tubal factor group (70.5 and 71.9%,
respectively, p=0.805).
Women with stage III–IV endometriosis were also directly
compared with women with stage I–II endometriosis. The
results of this analysis are reported in Table 4. Despite a
significantly higher fertilization rate, women with moderate
to severe endometriosis had a significantly lower pregnancy
rate (clinical pregnancy rate per embryo transfer 9.7 vs. 25%,
p=0.044). Women with more severe stages of endometriosis,
compared to women with minimal/mild endometriosis, also
had a lower peak E2 concentration, fewer follicles on the day
of hCG, fewer oocytes at retrieval and a lower implantation
rate.
In the stage III–IV endometriosis group the cycle was dis-
continued because of poor ovarian response in 15 of 109
cycles (13.8%) compared with only three cycles of 80 (3.7%)
in the tubal factor group and two of 55 (3.6%) in the mini-
mal/mild endometriosis group.
Discussion
Endometriosis has become a frequent indication for IVF-ET.
Whether endometriosis influences the results of IVF-ET re-
mains a controversial issue. A number of studies have exam-
ined IVF-ET outcomes in women with endometriosis, with
conflicting evidence. In a systematic review, a reduced re-
sponse to gonadotropins, lower oocyte yield and poor clinical
pregnancy rates per cycle have all been described in patients
with endometriosis compared with women with tubal infer-
tility (4). Some studies have reported IVF-ET success rates in
endometriosis comparable to those in unexplained or tubal
factor infertility or improved outcomes with increasing dis-
ease stage (7–9).
Our study showed a detrimental relation between ad-
vanced stage endometriosis and IVF-ET outcome, with a
significant reduction in pregnancy rates (clinical pregnancy
rate per embryo transfer: 9.7% for stage III–IV, 25% for
stage I–II and 26.1% for tubal factor). Almost all aspects
of IVF-ET negatively influenced women previously treated
for severe endometriosis, including peak estradiol concen-
trations, number of follicles on the day of hCG, number of
oocytes retrieved and implantation rates.
The negative association between moderate/severe en-
dometriosis and the number of oocytes retrieved might be
ascribed to the effect of previous surgical treatment more
than to the disease endometriosis itself. Ovarian cystectomy
has been associated with damage to healthy ovarian tissue
and reduction in ovarian reserve (10,11). Furthermore, in
patients with more severe stages, major pelvic adhesions (in-
cluding those that result from endometriosis) can impair
oocyte release from the ovary or inhibit ovum pick-up or
transport (12,13). Our data support the defective implanta-
tion in stage III–IV previously described. Lack of understand-
ing with regard to the mechanisms of embryo implantation
makes it difficult to explain why women with endometriosis
may have a decreased implantation capacity (14). Reduced
endometrial receptivity might be secondary to delayed his-
tological maturation or biochemical disorders, reduction of
αvβ3 integrin expression or dysregulation of other select
genes in the endometrium (14).
Aboulghar et al. reported that the outcome of IVF-ET in
stage IV endometriosis with previous surgery was signifi-
cantly lower with a cycle cancellation in 29.7% of the study
group compared with 1.1% in the control group (14). Our
data confirmed a decrease in ovarian responsiveness to go-
nadotropins and diminished ovarian reserve in women previ-
ously treated for moderate-severe endometriosis (cycle can-
cellation rate 13.8% in endometriosis stages III–IV vs. 3.6%
in endometriosis stages I–II and 3.7% in tubal factor group).
In contrast, the fertilization rate in women with severe en-
dometriosis was similar to that in women with tubal factor
infertility and higher compared to women with mild en-
dometriosis. This finding is in line with other studies (16,17).
Aboulghar et al. hypothesized that one possible reason for this
may be that lesions associated with severe endometriosis of-
ten do not have active endometrial glands, but instead are
‘burned-out’ lesions resulting in pelvic adhesions (15).
Women with minimal/mild endometriosis showed a sig-
nificantly reduced fertilization rate when compared with
both stage III–IV and tubal factor. When comparing min-
imal/mild endometriosis and tubal factor for the other pa-
rameters, the result was similar. The negative influence on
fertility of moderate and severe endometriosis is plausible
because of impaired tubal motility and ovum pick-up func-
tion. In cases of minimal/mild endometriosis with no appar-
ent structural damage, the etiological basis for infertility is
still unclear. Moreover, stage I–II of endometriosis is usually
diagnosed through laparoscopy, and its prevalence among
infertile women is probably underestimated.
In the management of fertility problems associated with
endometriosis, it is widely accepted that endometriosis
stage I–II may be considered equivalent to unexplained infer-
tility and managed accordingly (National Institute for Health
and Clinical Excellence guidelines). According to Vercellini
et al., minimal/mild endometriosis could represent a tem-
porary phase in an ongoing process that usually results in
cytolysis of recently implanted endometrial cells (18).
In contrast, there is evidence that surgical treatment of
minimal and mild endometriosis increases fecundity in
infertile patients. A systematic review and meta-analysis
of two randomized controlled trials (n=444) showed
that laparoscopic ablation or resection of minimal and
mild endometriosis plus laparoscopic adhesiolysis increased
1236
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ongoing pregnancy and live birth rates compared with diag-
nostic laparoscopy (pooled odds ratio 1.64; 95% confidence
interval 1.05–2.57; 19). In a recent study we observed that in
stages I and II the first six-month fecundity rate after laparo-
scopic surgery was 27%, and it was not significantly different
from the fecundity rate of 17% of the following six months
(months seven to 12). The fecundity rate dropped signifi-
cantly to 4% after one year, and there were no conceptions
after 60months (20). Furthermore, it has been shown that
women with mild endometriosis have an increased volume
of peritoneal fluid, containing more activated inflammatory
factors. Peritoneal fluid can influence reproductive processes
by modulating the microenvironment. It seems reasonable
that a hostile peritoneal and/or tubal environment may be
considered as a possible cause of infertility in women with
stage I–II endometriosis (21). In a recent study, Ding et al.
observed that when oocytes and embryos were cultured
in media with peritoneal fluid obtained from infertile
women with mild endometriosis, the fertilization capability
of oocytes and the development potential of embryos were de-
creased. They concluded that endometriotic peritoneal fluid
may attenuate oocyte and embryo development by impairing
the embryonic growth factor/receptor/signal transduction,
resulting in endometriotic infertility (21). Our observation
demonstrated that the fecundity rate dropped significantly
to 4% one year after surgery. In patients surgically treated for
endometriosis, the peritoneal fluid containing activated in-
flammatory factors might progressively increase after surgery.
In this scenario, IVF-ET could act by removing oocytes from
a hostile environment.
The strength of the present study is the carefully selected
homogeneous groups of patients in both the study and the
control groups. By excluding women older than 35 years
and/or with clinical/ultrasonographic sign of recurrences at
the time of the IVF-ET cycle we obtained two comparable
groups. Moreover, women with endometriosis showed fertil-
ity problems before surgery, thus not necessarily due to the
possible effect of surgery.
The lack of studies conducted on homogeneous groups
may be an important reason for confusing and contradictory
data in the literature on the effect of endometriosis on IVF-ET
outcomes. Limiting a clinical trial to a homogeneous group
of participants lessens potential confounders. Obviously, the
strict criteria followed for the selection in our study led to a
reduction of the number of patients included. In addition, the
retrospective analysis and the lack of a diagnostic laparoscopy
before IVF-ET in both groups to ascertain the absence of
minimal endometriotic lesions might further limit the power
of the study. However, it would be unethical to submit these
patients to laparoscopy before the IVF-ET cycle.
The cause and effect relation between endometriosis and
infertility is difficult to study because of the multiple mech-
anisms through which endometriosis may interfere with fer-
tility. The IVF-ET cycle consists of several steps, each one
of which can be analyzed individually for the effect of en-
dometriosis on reproductive function.
These results suggest that different stages of endometrio-
sis might interfere with IVF-ET outcome through different
effects and mechanisms. For moderate/severe stages, we ob-
served the deleterious effect on IVF-ET cycles in terms of
cancellation rate, poor responsiveness and implantation rate.
Stage I–II showed a significantly impaired fertilization rate.
The ASRM classification proved useful in predicting the
outcome of infertility treatment and might be used for
planning and counseling purposes. Future research in en-
dometriosis is needed to clarify these mechanisms and should
focus on homogeneous groups of patients and stratify re-
sults on the basis of ASRM stages. Our results suggest that
clinical trials on endometriosis patients need to differentiate
between stages (I–II vs. III–IV) to have more homogeneous
and nonconfusing data due to different interference of the
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